JP2004509869A - 二重ヒスタミンｈ１およびｈ３アゴニストまたはアンタゴニストとしての、置換されたイミダゾール - Google Patents

二重ヒスタミンｈ１およびｈ３アゴニストまたはアンタゴニストとしての、置換されたイミダゾール Download PDF

Info

Publication number
JP2004509869A
JP2004509869A JP2002529069A JP2002529069A JP2004509869A JP 2004509869 A JP2004509869 A JP 2004509869A JP 2002529069 A JP2002529069 A JP 2002529069A JP 2002529069 A JP2002529069 A JP 2002529069A JP 2004509869 A JP2004509869 A JP 2004509869A
Authority
JP
Japan
Prior art keywords
compound
group
compounds
pharmaceutical composition
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002529069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509869A5 (es
Inventor
シー，　ネン−ヤン
アスラニアン，　ロバート　ジー．
ピウィンスキ，　ジョン　ジェイ．
ルポ，　アンドリュー　ティー．　ジュニア
アフォンソ，　アドリアノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2004509869A publication Critical patent/JP2004509869A/ja
Publication of JP2004509869A5 publication Critical patent/JP2004509869A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002529069A 2000-09-20 2001-09-18 二重ヒスタミンｈ１およびｈ３アゴニストまたはアンタゴニストとしての、置換されたイミダゾール Pending JP2004509869A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23403800P 2000-09-20 2000-09-20
PCT/US2001/029037 WO2002024657A2 (en) 2000-09-20 2001-09-18 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists

Publications (2)

Publication Number Publication Date
JP2004509869A true JP2004509869A (ja) 2004-04-02
JP2004509869A5 JP2004509869A5 (es) 2008-09-11

Family

ID=22879621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002529069A Pending JP2004509869A (ja) 2000-09-20 2001-09-18 二重ヒスタミンｈ１およびｈ３アゴニストまたはアンタゴニストとしての、置換されたイミダゾール

Country Status (14)

Country Link
US (1) US6528522B2 (es)
EP (1) EP1318993B1 (es)
JP (1) JP2004509869A (es)
CN (1) CN1558907A (es)
AR (1) AR031612A1 (es)
AT (1) ATE405557T1 (es)
AU (1) AU2001291040A1 (es)
CA (1) CA2422210C (es)
DE (1) DE60135471D1 (es)
ES (1) ES2311544T3 (es)
HK (1) HK1052180A1 (es)
MX (1) MXPA03002445A (es)
MY (1) MY120281A (es)
WO (1) WO2002024657A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016508521A (ja) * 2013-02-19 2016-03-22 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗腫瘍剤としての三環式複素環

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
EP3347355B1 (en) 2015-09-09 2022-07-13 Icahn School of Medicine at Mount Sinai Heterotricyclic sulfonamides as anti-cancer agents
US10221158B2 (en) 2015-09-09 2019-03-05 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
ES2058651T3 (es) 1990-03-30 1994-11-01 Heumann Pharma Gmbh & Co Uso derivados de guanidina para la fabricacion de un medicamento con actividad antagonista de npy.
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
JP2540015B2 (ja) 1991-12-18 1996-10-02 シェリング・コーポレーション ヒスタミンｈ▲下３▼アゴニスト／アンタゴニストとしてのイミダゾリル−アルキル−ピペラジンおよび−ジアゼピン誘導体
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
JP2002515912A (ja) 1997-06-24 2002-05-28 ノボ ノルディスク アクティーゼルスカブ 目に関連する病気の処置のためのソマトスタチン作動因子及び拮抗因子の利用
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016508521A (ja) * 2013-02-19 2016-03-22 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗腫瘍剤としての三環式複素環

Also Published As

Publication number Publication date
DE60135471D1 (de) 2008-10-02
CN1558907A (zh) 2004-12-29
US6528522B2 (en) 2003-03-04
ATE405557T1 (de) 2008-09-15
US20020082272A1 (en) 2002-06-27
HK1052180A1 (zh) 2003-09-05
AR031612A1 (es) 2003-09-24
MY120281A (en) 2005-09-30
MXPA03002445A (es) 2003-06-19
ES2311544T3 (es) 2009-02-16
EP1318993A2 (en) 2003-06-18
CA2422210A1 (en) 2002-03-28
AU2001291040A1 (en) 2002-04-02
EP1318993B1 (en) 2008-08-20
WO2002024657A3 (en) 2002-07-11
WO2002024657A2 (en) 2002-03-28
CA2422210C (en) 2009-10-27

Similar Documents

Publication Publication Date Title
JP4211394B2 (ja) プロパン−１，３−ジオン誘導体
JP4563800B2 (ja) ヒスタミンｈ３アンタゴニストとしての１−（４−ピペリジニル）ベンズイミダゾロン
JP2001518895A (ja) ソマトスタチン作働薬
JP2002539121A (ja) ヒスタミンｈ３リガンドとしてのイミダゾール化合物
WO2003045921A1 (en) Heterocyclic amide compounds as apolipoprotein b inhibitors
US6127343A (en) Somatostatin agonists and antagonists
US6133291A (en) N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
US6762186B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
US6506756B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
US6528522B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
US6518287B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
EP1472226A1 (en) Heterocyclic amide compounds as apolipoprotein b inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120307